Stock listing
NASDAQ:REGN Regeneron Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Regeneron Pharmaceuticals, Inc.
Follow Regeneron Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:REGN
$920.69 USD -24.84 (-2.6%)
Close on Nov 20, 2026
- Day range
- $916.66 – $948.42 USDNov 20, 2026
- Volume
- 877,666 sharesNov 20, 2026
- Market cap
- $93.57B USDAt the close on Nov 20, 2026 · price × 101.6M shares outstanding
- 52-week range
- $591.52 – $991.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $667.9M USDMedian day 682,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:REGN · Home | $920.69 USD | -24.84 (-2.6%) | 877,666 | $936.37 | $948.42 | $916.66 | $945.53 | Close on Nov 20, 2026 |
| B3:REGN34 | 92.08 BRL | -0.43 (-0.5%) | 146 | 92.51 | 93.72 | 91.44 | 92.51 | Close on Nov 19, 2026 |
| Frankfurt:RGO | €837.10 EUR | -7.70 (-0.9%) | 26 | €839.10 | €839.10 | €837.10 | €844.80 | Close on Nov 20, 2026 |
| LSE:0R2M | $921.17 USD | -9.465 (-1.0%) | 886 | $939.65 | $948.44 | $918.00 | $930.63 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:REGN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $920.69 | -24.84 | -2.6% | $936.37 | $948.42 | $916.66 | 877,666 | |
| $945.53 | -12.23 | -1.3% | $957.25 | $972.00 | $943.26 | 704,317 | |
| $957.76 | +5.36 | +0.6% | $952.56 | $965.48 | $946.94 | 928,098 | |
| $952.40 | -3.07 | -0.3% | $964.00 | $971.67 | $947.89 | 700,518 | |
| $955.47 | +4.28 | +0.4% | $952.47 | $961.94 | $942.00 | 927,985 | |
| $951.19 | -8.22 | -0.9% | $971.85 | $981.55 | $944.71 | 1,028,860 | |
| $959.41 | +43.35 | +4.7% | $904.99 | $961.98 | $899.00 | 1,220,674 | |
| $916.06 | -3.90 | -0.4% | $915.34 | $919.72 | $905.38 | 516,987 | |
| $919.96 | +15.61 | +1.7% | $922.00 | $933.36 | $901.07 | 854,548 | |
| $904.35 | +1.45 | +0.2% | $887.22 | $911.57 | $887.22 | 1,119,227 | |
| $902.90 | -27.77 | -3.0% | $938.51 | $948.06 | $901.59 | 1,398,322 | |
| $930.67 | -42.69 | -4.4% | $989.90 | $991.73 | $927.42 | 1,383,132 | |
| $973.36 | +12.10 | +1.3% | $956.28 | $975.49 | $953.00 | 1,198,080 | |
| $961.26 | +33.37 | +3.6% | $927.22 | $974.00 | $927.00 | 1,660,934 | |
| $927.89 | +109.12 | +13.3% | $869.43 | $935.34 | $839.08 | 2,851,725 | |
| $818.77 | +5.50 | +0.7% | $826.14 | $828.19 | $811.63 | 781,724 | |
| $813.27 | -2.83 | -0.3% | $806.20 | $821.16 | $802.20 | 533,560 | |
| $816.10 | +8.43 | +1.0% | $807.67 | $816.14 | $804.17 | 716,874 | |
| $807.67 | +2.65 | +0.3% | $812.31 | $817.17 | $796.61 | 418,085 | |
| $805.02 | -14.07 | -1.7% | $819.09 | $819.09 | $801.22 | 527,718 | |
| $819.09 | +13.42 | +1.7% | $809.72 | $825.52 | $800.00 | 852,286 | |
| $805.67 | -1.81 | -0.2% | $806.74 | $813.86 | $800.24 | 578,415 | |
| $807.48 | +25.44 | +3.3% | $794.66 | $807.86 | $789.69 | 619,494 | |
| $782.04 | -8.70 | -1.1% | $792.59 | $800.00 | $780.83 | 489,437 | |
| $790.74 | -5.60 | -0.7% | $803.01 | $805.68 | $787.32 | 653,500 | |
| $796.34 | +17.98 | +2.3% | $802.33 | $809.49 | $792.58 | 798,800 | |
| $778.36 | +25.24 | +3.4% | $758.16 | $781.84 | $755.21 | 878,400 | |
| $753.12 | -9.69 | -1.3% | $762.49 | $765.60 | $743.57 | 629,600 | |
| $762.81 | +16.27 | +2.2% | $748.67 | $768.66 | $744.96 | 618,200 | |
| $746.54 | +6.97 | +0.9% | $737.20 | $751.27 | $732.83 | 466,000 | |
| $739.57 | -2.55 | -0.3% | $742.12 | $744.50 | $723.65 | 500,300 | |
| $742.12 | +3.40 | +0.5% | $738.05 | $753.68 | $734.18 | 626,400 | |
| $738.72 | +12.25 | +1.7% | $734.61 | $740.51 | $727.16 | 615,100 | |
| $726.47 | -8.73 | -1.2% | $734.37 | $736.42 | $722.02 | 694,700 | |
| $735.20 | +0.39 | +0.1% | $740.50 | $742.50 | $729.20 | 613,900 | |
| $734.81 | -23.46 | -3.1% | $766.53 | $777.43 | $726.02 | 1,042,800 | |
| $758.27 | +7.76 | +1.0% | $749.84 | $763.72 | $742.94 | 872,400 | |
| $750.51 | -1.74 | -0.2% | $745.85 | $752.47 | $741.83 | 804,300 | |
| $752.25 | -35.79 | -4.5% | $778.09 | $780.95 | $750.00 | 1,149,800 | |
| $788.04 | -7.98 | -1.0% | $803.87 | $803.87 | $784.13 | 592,100 | |
| $796.02 | -5.80 | -0.7% | $801.59 | $807.21 | $789.39 | 602,600 | |
| $801.82 | -2.08 | -0.3% | $805.23 | $813.53 | $790.02 | 721,100 | |
| $803.90 | +5.73 | +0.7% | $802.48 | $811.66 | $791.31 | 600,200 | |
| $798.17 | +13.32 | +1.7% | $786.03 | $801.44 | $779.96 | 704,400 | |
| $784.85 | -4.60 | -0.6% | $787.34 | $794.73 | $779.65 | 2,473,436 | |
| $789.45 | +14.84 | +1.9% | $781.18 | $789.99 | $774.78 | 702,816 | |
| $774.61 | +0.50 | +0.1% | $775.82 | $779.98 | $771.80 | 382,900 | |
| $774.11 | -19.63 | -2.5% | $788.53 | $788.58 | $769.57 | 540,600 | |
| $793.74 | +12.25 | +1.6% | $791.98 | $798.84 | $779.45 | 591,100 | |
| $781.49 | -11.77 | -1.5% | $800.00 | $800.22 | $780.81 | 444,000 | |
| $793.26 | -14.39 | -1.8% | $794.36 | $806.14 | $792.00 | 526,900 | |
| $807.65 | -2.66 | -0.3% | $803.83 | $808.63 | $796.73 | 621,400 | |
| $810.31 | -17.41 | -2.1% | $814.36 | $821.17 | $799.42 | 556,500 | |
| $827.72 | -15.75 | -1.9% | $840.06 | $841.54 | $825.83 | 561,100 | |
| $843.47 | -8.56 | -1.0% | $858.19 | $859.34 | $837.63 | 496,200 | |
| $852.03 | +28.21 | +3.4% | $826.24 | $854.49 | $825.77 | 749,400 | |
| $823.82 | +24.74 | +3.1% | $808.86 | $824.63 | $804.32 | 682,600 | |
| $799.08 | +4.89 | +0.6% | $782.44 | $802.78 | $779.08 | 894,100 | |
| $794.19 | -13.52 | -1.7% | $809.40 | $809.40 | $789.08 | 488,305 | |
| $807.71 | -7.08 | -0.9% | $806.18 | $817.62 | $804.27 | 766,800 | |
| $814.79 | -18.77 | -2.3% | $827.78 | $831.67 | $814.70 | 585,300 | |
| $833.56 | +5.06 | +0.6% | $829.22 | $839.94 | $823.44 | 505,400 | |
| $828.50 | -5.54 | -0.7% | $834.51 | $834.70 | $823.40 | 672,000 | |
| $834.04 | +7.40 | +0.9% | $835.74 | $847.00 | $826.64 | 786,800 | |
| $826.64 | -14.20 | -1.7% | $831.70 | $840.82 | $826.05 | 596,400 |
- Ticker
- NASDAQ:REGN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
Latest earnings call · Oct 30, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 34 slides
Latest news
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
Nov 19, 2026
Closed $920.69 (-2.6%) on Nov 20, 2026
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Nov 18, 2026
Closed $920.69 (-2.6%) on Nov 20, 2026
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
Nov 17, 2026
Closed $957.76 (+0.6%) on Nov 17, 2026
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Nov 12, 2026
Closed $955.47 (+0.4%) on Nov 13, 2026
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Nov 8, 2026
Closed $919.96 (+1.7%) on Nov 9, 2026
Mary Tyler Moore Vision Initiative Welcomes Regeneron and Adaptive Sensory Technology to Its Consortium
Nov 5, 2026
Closed $902.90 (-3.0%) on Nov 5, 2026
Issued by another party
Regeneron Announces Investor Conference Presentations
Nov 2, 2026
Closed $973.36 (+1.3%) on Nov 3, 2026
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Oct 30, 2026
Closed $927.89 (+13.3%) on Oct 30, 2026
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Oct 26, 2026
Closed $807.67 (+0.3%) on Oct 26, 2026
Regeneron Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 71 in the last 12 months · 374 in all · newest Nov 19, 2026 · oldest 2020
- Calls
- 32 calls with a replay · 32 with a transcript · latest Oct 30, 2026
- Decks
- 64 decks · latest July 2026
Where Regeneron Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:REGN · Home listing · This page | NASDAQ | United States | USD |
| gettex:RGO | gettex | Germany | EUR |
| LS Exchange:881535 | LS Exchange | Germany | EUR |
| Tradegate:RGO | Tradegate | Germany | EUR |
| BMV:REGN | BMV | Mexico | MXN |
| B3:REGN34 | B3 | Brazil | BRL |
| BOATS:REGN | BOATS | United States | USD |
| Frankfurt:RGO | Frankfurt | Germany | EUR |
| LSE:0R2M | LSE | United Kingdom | USD |
| Lang & Schwarz:881535 | Lang & Schwarz | Germany | EUR |
| Dusseldorf:RGO | Dusseldorf | Germany | EUR |
| VIE:REGN | Vienna | Austria | EUR |
| BIVA:REGN | BIVA | Mexico | MXN |
| Stuttgart:RGO | Stuttgart | Germany | EUR |
| Milan:1REGN | Milan | Italy | EUR |
| Munich:RGO | Munich | Germany | EUR |
| Turquoise:REGNN | Turquoise | United Kingdom | USD |
| Xetra:RGO | Xetra | Germany | EUR |
| EUROTLX:4REGN | EUROTLX | Italy | EUR |
| BX Swiss:RGO | BX Swiss | Switzerland | CHF |
| Hanover:RGO | Hanover | Germany | EUR |
| BVL:REGNUS | BVL | Peru | PEN |
| Hamburg:RGO | Hamburg | Germany | EUR |
Valuation
P/E 19.4× against a median of 21.5×: 4th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $86.26B USD
- P/E
- 19.4×
- EV/sales
- 5.1×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.8×
- Gross margin
- Not reported
- Operating margin
- 28.8%
- Net margin
- 28.5%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.36
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN | US$93.57B | US$86.26B | 19.4× | 5.1× | n/a | 2.8× | 28.5% | 0.1× | 0.36 |
| Amgen Inc. · NASDAQ:AMGN | US$235.6B | US$276.5B | 25.1× | 7.1× | 15.8× | 16.4× | 24.1% | 3.8× | 0.48 |
| Gilead Sciences, Inc. · NASDAQ:GILD | US$206.4B | US$226.2B | n/a | 7.3× | n/a | 15.8× | −12.5% | 2.0× | 0.36 |
| CSL Limited · ASX:CSL | US$62.67B | US$72.05B | n/a | 4.6× | 14.3× | 4.2× | −16.4% | 0.7× | n/a |
| Biogen Inc. · NASDAQ:BIIB | US$36.89B | US$42.88B | 106× | 4.2× | n/a | 1.9× | 3.4% | 0.4× | 0.34 |
| Genmab A/S · OMXCOP:GMAB | US$31.30B | US$34.64B | 42.9× | 8.1× | 24.4× | 4.9× | 17.0% | 0.8× | n/a |
| Insmed Incorporated · NASDAQ:INSM | US$31.01B | US$30.41B | n/a | 20.0× | n/a | 42.7× | −39.9% | 0.8× | 0.01 |
| Roivant Sciences Ltd. · NASDAQ:ROIV | US$27.92B | US$23.82B | n/a | 580× | n/a | 7.0× | −838.2% | 0.0× | 1.00 |
| Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY | US$19.26B | US$15.68B | 7.3× | n/a | n/a | 5.3× | n/a | 0.0× | 0.58 |
| Ascendis Pharma A/S · NASDAQ:ASND | US$16.73B | US$16.15B | 17.1× | 12.2× | 61.1× | 10.0× | 73.5% | 0.3× | 0.49 |
| Exelixis, Inc. · NASDAQ:EXEL | US$15.77B | US$14.88B | 17.8× | 6.0× | n/a | 8.6× | 35.4% | 0.0× | 0.69 |
| Median of the others | US$31.15B | US$32.52B | 21.5× | 7.3× | 20.1× | 7.8× | 3.4% | 0.6× | 0.49 |
Forecasts
15 strong buy · 4 buy · 9 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 984.96 USD · Analysts' mean
- EPS, year to Dec 2026
- 69.01 · 25 analysts
- Revenue, year to Dec 2026
- 18.81B · 25 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Leonard S. Schleifer | Board co-Chair, President and Chief Executive Officer |
| Tony Coles | Chair and former CEO, Cerevel |
| Chris Fenimore | Executive Vice President, Finance and Chief Financial Officer |
| George D. Yancopoulos | Board co-Chair, President and Chief Scientific Officer |
| George Fraley | Senior Vice President, Associate General Counsel |
| Joseph J. LaRosa | Executive Vice President, General Counsel and Secretary |
| Larry Coury | Senior Vice President, Associate General Counsel |
| Richard Gluckselig | Senior Vice President, Associate General Counsel & Assistant Secretary |
| Alexandra Bowie | Regeneron Investor Relations |
| Christina Chan | Corporate Communications |
| Ilana Yellen | Regeneron Investor Relations |
| Kailey Kilmartin | Regeneron Investor Relations |
| Mark Hudson | Investor Relations |
| Ryan Crowe | Senior Vice President, Investor Relations & Strategic Analysis |
| Sharon Chen | Regeneron Investor Relations |
| Andrew Murphy | Executive Vice President, Research and Co-Chief Scientific Officer |
| Benjamin Yocum | Senior Vice President, Manufacturing Operations |
| Brook Jennings | Senior Vice President, Global Immunology Commercial Business Unit |
| Daniel Van Plew | Executive Vice President and General Manager, Industrial Operations and Product Supply |
| Danilo Verge | Senior Vice President, Global Medical Affairs |
| Diana Hughes | Senior Vice President, Global Patient Safety |
| Divya Pathak | Senior Vice President, Chief Artificial Intelligence Officer |
| John Calabro | Senior Vice President, Internal Audit |
| Justin Holko | Senior Vice President, Global Oncology/Hematology Commercial Business Unit |
| Kerry Reinertsen | Senior Vice President, Strategic Alliances |
| Kevin Clark | Senior Vice President, Global Ophthalmology Commercial Business Unit |
| L. Andres Sirulnik | Senior Vice President, Clinical Development Unit Head, Hematology |
| Mack MacKenzie | Senior Vice President, Commercial and G&A Digital & Technology |
| Marion McCourt | Executive Vice President, Commercial |
| Matthew Everett | Senior Vice President, Global Procurement |
| Melissa Lozner | Senior Vice President, Chief Compliance Officer |
| Ned Braunstein | Executive Vice President, Regulatory Affairs, Global Patient Safety & Development Quality |
| Rick Hall | Senior Vice President, Human Resources and Chief Human Resources Officer |
| Ryan Steinberger | Executive Vice President, Chief Digital & Technology Officer |
| Zoran Berkovic | Senior Vice President, Financial Planning and Analysis |
Board
| Director | Role |
|---|---|
| Bonnie L. Bassler | Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University |
| Joseph L. Goldstein | Professor of Molecular Genetics and Internal Medicine and Chair, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas |
| Michael S. Brown | Distinguished Chair in Biomedical Sciences, Regental Professor of Molecular Genetics and Internal Medicine, and Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southweste |
| Tony Coles | Chair and former CEO, Cerevel |
| David Snow | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Call | Fri, Oct 30, 2026 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2025 Earnings Call | Fri, Jan 30, 2026 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Call | Tue, Oct 28, 2025 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2025 Earnings Call | Fri, Aug 01, 2025 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2024 Earnings Call | Tue, Feb 04, 2025 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2024 Earnings Call | Thu, Oct 31, 2024 · 8:30 AM ET | Replay |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 8:30 AM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 · Before open | +13.3% |
| Q2 2026 | Jul 30, 2026 · Before open | +6.2% |
| Q1 2026 | Apr 29, 2026 · Before open | −6.2% |
| Q4 2025 | Jan 30, 2026 · Before open | −1.1% |
| Q3 2025 | Oct 28, 2025 · Before open | +11.8% |
| Q2 2025 | Aug 1, 2025 · Before open | +2.5% |
| Q1 2025 | Apr 29, 2025 · Before open | −6.9% |
| Q4 2024 | Feb 4, 2025 · Before open | +4.5% |
| Q3 2024 | Oct 31, 2024 · Before open | −9.2% |
| Q2 2024 | Aug 1, 2024 · Before open | +1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +3.8% |
| Q4 2023 | Feb 2, 2024 · Before open | −1.3% |
| Q3 2023 | Nov 2, 2023 · Before open | +3.5% |
| Q2 2023 | Aug 3, 2023 · Before open | +5.4% |
| Q1 2023 | May 4, 2023 · Before open | −6.1% |
| Q4 2022 | Feb 3, 2023 · Before open | +4.3% |
| Q3 2022 | Nov 3, 2022 · Before open | −0.2% |
| Q2 2022 | Aug 3, 2022 · Before open | +5.9% |
| Q1 2022 | May 4, 2022 · Before open | +0.1% |
| Q4 2021 | Feb 4, 2022 · Before open | +0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 34 slides | July 2026 |
| Q1 2026 Earnings Presentation | Earnings | 36 slides | Apr 29, 2026 |
| Investor Presentation (April 2026) | Investor deck | 40 slides | Apr 22, 2026 |
| Technical Presentation (February 2026) | Technical | 19 slides | Feb 7, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 35 slides | Jan 30, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 19 slides | Jan 12, 2026 |
| Shareholder Meeting (2026) | Shareholder meeting | 24 slides | 2026 |
| Investor Day (December 2025) | Investor day | 31 slides | Dec 10, 2025 |
| Investor Day (November 2025) | Investor day | 36 slides | Nov 10, 2025 |
| Investor Presentation (October 2025) | Investor deck | 38 slides | October 2025 |
Show 50 decks
This page holds 50 of 64 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.3B | 14.2B | 13.1B | 12.2B | 16.1B | 8.50B | 6.56B | 5.15B | 5.87B | 4.86B |
| Cost of revenue | 402.8M | 237.5M | 202.5M | 194.6M | ||||||
| Gross profit | 6.15B | 4.91B | 5.67B | 4.67B | ||||||
| Research and development | 5.85B | 5.13B | 4.44B | 3.59B | 2.86B | 2.65B | 2.45B | 1.47B | 2.08B | 2.05B |
| Selling, general and administrative | 2.70B | 2.95B | 2.63B | 2.12B | 1.82B | 1.35B | 1.34B | 1.13B | 1.32B | 1.18B |
| Operating income | 3.58B | 3.99B | 4.05B | 4.74B | 8.95B | 3.58B | 2.21B | 2.53B | 2.08B | 1.33B |
| Depreciation and amortization | 543.7M | 482.9M | 421.0M | 341.4M | 286.2M | 235.9M | 210.3M | 148.2M | 145.5M | 104.7M |
| EBITDA | 4.12B | 4.47B | 4.47B | 5.08B | 9.23B | 3.81B | 2.42B | 2.68B | 2.23B | 1.44B |
| Interest expense | 43.8M | 55.2M | 73.0M | 59.4M | 57.3M | 56.9M | 30.2M | 28.2M | 25.1M | 7.20M |
| Income before tax | 5.23B | 4.78B | 4.20B | 4.86B | 9.33B | 3.81B | 2.43B | 2.55B | 2.08B | 1.33B |
| Income tax | 725.8M | 367.3M | 245.7M | 520.4M | 1.25B | 297.2M | 313.3M | 109.1M | 880.0M | 434.3M |
| Net income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B | 2.12B | 2.44B | 1.20B | 895.5M |
| Earnings per share, basic | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 |
| Earnings per share, diluted | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.12B | 2.49B | 2.73B | 3.11B | 2.89B | 2.19B | 1.62B | 1.47B | 812.7M | 535.2M |
| Short-term investments | 5.49B | 6.52B | 8.11B | 4.64B | 2.81B | 1.39B | 1.60B | 1.34B | 596.8M | 503.5M |
| Receivables | 5.74B | 6.21B | 5.67B | 5.33B | 6.04B | 4.11B | 2.10B | 1.72B | 1.54B | 1.34B |
| Inventory | 3.20B | 3.09B | 2.58B | 2.40B | 1.95B | 1.92B | 1.42B | 1.15B | 726.1M | 399.4M |
| Current assets | 18.0B | 18.7B | 19.5B | 15.9B | 14.0B | 9.78B | 7.69B | 6.45B | 4.33B | 3.18B |
| Property, plant and equipment | 3.48B | 3.22B | 2.89B | 2.58B | 2.36B | 2.08B | ||||
| Total assets | 40.6B | 37.8B | 33.1B | 29.2B | 25.4B | 17.2B | 14.8B | 11.7B | 8.76B | 6.97B |
| Accounts payable | 939.0M | 789.5M | 606.6M | 589.2M | 564.0M | 475.5M | 418.1M | 218.2M | 178.2M | |
| Current liabilities | 4.37B | 3.94B | 3.42B | 3.14B | 3.93B | 2.70B | 2.10B | 1.44B | 1.14B | 1.24B |
| Long-term debt | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 0 | |||
| Total debt | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 0 | |||
| Total liabilities | 9.30B | 8.41B | 7.11B | 6.55B | 6.67B | 6.14B | 3.72B | 2.98B | 2.62B | 2.52B |
| Shareholders' equity | 31.3B | 29.4B | 26.0B | 22.7B | 18.8B | 11.0B | 11.1B | 8.76B | 6.14B | 4.45B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4.98B | 4.42B | 4.59B | 5.01B | 7.08B | 2.62B | 2.43B | 2.20B | 1.31B | 1.49B |
| Capital spending | -898.4M | -755.9M | -718.6M | -590.1M | -551.9M | -614.6M | -429.6M | -383.1M | -272.6M | -511.9M |
| Free cash flow | 4.08B | 3.66B | 3.88B | 4.42B | 6.53B | 2.00B | 2.00B | 1.81B | 1.03B | 974.0M |
| Cash from investing | -629.1M | -2.47B | -3.19B | -3.78B | -5.38B | -70.6M | -2.03B | -1.46B | -1.01B | -1.05B |
| Cash from financing | -3.72B | -2.20B | -1.79B | -1.01B | -1.01B | -1.97B | -252.1M | -77.1M | -24.4M | -700.5M |
| Dividends paid | -370.3M | 0 | 0 | |||||||
| Share buybacks | -3.44B | -2.60B | -2.23B | -2.08B | -1.65B | -5.85B | -275.9M | -4.40M | 0 | 0 |
| Change in cash | 634.7M | -248.8M | -381.6M | 221.3M | 690.8M | 577.0M | 150.1M | 655.0M | 277.5M | -261.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Nov 19, 2026 | Offer document | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 13F-HR · Fund holdings report | Nov 5, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 14, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 6, 2026 | Results | SEC |
| 8-K · Current report | Sep 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| N-PX | Aug 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 13F-HR · Fund holdings report | Aug 7, 2026 | Fund holdings report | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 13F-HR · Fund holdings report | May 8, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 13F-HR · Fund holdings report | Feb 6, 2026 | Fund holdings report | SEC |
| 10-K · Annual report | Feb 4, 2026 | Annual report | SEC |
| 8-K · Current report | Jan 30, 2026 | Results | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 7, 2025 | Other filings | SEC |
| 13F-HR · Fund holdings report | Nov 7, 2025 | Fund holdings report | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 28, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2025 | Results | SEC |
| 8-K · Current report | Oct 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 13F-HR · Fund holdings report | Aug 1, 2025 | Fund holdings report | SEC |
| 10-Q · Quarterly report | Aug 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2025 | Results | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2025 | Big-stake notice | SEC |
| 13F-HR · Fund holdings report | May 2, 2025 | Fund holdings report | SEC |
| 10-Q · Quarterly report | Apr 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 22, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Apr 17, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 7, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 21, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 13F-HR · Fund holdings report | Feb 7, 2025 | Fund holdings report | SEC |
| 10-K · Annual report | Feb 5, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 4, 2025 | Results | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| S-3ASR · Registration statement | Oct 31, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2024 | Results | SEC |
| 8-K · Current report | Oct 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 28, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 1, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
This page holds 200 of 1,003 filings. Open Filings
Cap table
Built by 6ix from Regeneron Pharmaceuticals, Inc.’s releases
- Common shares
- 101,630,713
- Fully diluted
- 101,630,713
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 101,630,713 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 101,630,713 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Alexander Ingram Other companies: Black Diamond Therapeutics, Inc. (Director · Sep 25, 2020 – Sep 16, 2022 · Past); Novan Inc (Director · Sep 20, 2016 – Jul 28, 2020 · Past); BioCryst Pharmaceuticals, Inc. (Director · Aug 5, 2015 – Feb 28, 2023 · Past); Pharmaceutical Product Development Inc (Director · May 18, 2011 – Dec 5, 2011 · Past); Bausch Health Companies Inc. (Director · Sep 28, 2010 – Mar 31, 2017 · Past); Wolfspeed, Inc. (Director · Dec 29, 2008 – Oct 17, 2018 · Past); Edwards Lifesciences Corporation (Director · May 12, 2006 – May 15, 2015 · Past); Osi Pharmaceuticals Inc (Director · Mar 16, 2006 – Jun 8, 2010 · Past); Valeant Pharmaceuticals International Inc (Director · Jan 1, 2006 – Sep 28, 2010 · Past); Lowe's Companies, Inc. (Director · Dec 31, 2005 – Mar 31, 2011 · Past); Nortel Networks Corporation (USA) (Director · Dec 30, 2005 – Mar 31, 2006 · Past) | Director · Apr 4, 2014 – May 22, 2015 · Past |
| David Schenkein Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Foundation Medicine Inc (Director · Sep 24, 2013 – Jun 16, 2016 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Jun 20, 2024 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Jun 18, 2020 · Past); Foghorn Therapeutics Inc. (General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past) | Director · Since at least Sep 8, 2023 |
| Bonnie Bassler Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 22, 2021); Royalty Pharma plc (Board Member · Since at least Jun 15, 2020); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past) | Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University · Since at least Sep 9, 2016 |
| Murray A Goldberg Other companies: Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Teva Pharmaceutical Industries Limited (Director · Jan 1, 2018 – Jun 11, 2019 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – May 18, 2020 · Past) | SVP Administration & Asst Secr · Jan 9, 2006 – Dec 16, 2014 · Past |
| Robert E. Landry Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 5, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Cytokinetics, Incorporated (Director · Since at least Feb 10, 2025) | EVP Finance CFO · Mar 31, 2022 – Feb 2, 2024 · Past |
| Tony Coles Other companies: Kineta Inc. (Executive Chair, Director · Dec 22, 2020 – Apr 1, 2021 · Past); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); McKesson Corporation (Director · Jul 25, 2018 – Aug 17, 2020 · Past) | Director · Since at least Jan 2, 2018 |
| Christine A. Poon Other companies: Neurocrine Biosciences, Inc. (Director · Since at least Apr 15, 2026); Prudential Financial, Inc. (Director · Since at least Mar 26, 2026) | Director · Since at least Nov 2, 2026 |
| Craig B Thompson Other companies: Charles River Laboratories International, Inc. (Director · Since at least Dec 3, 2013); Merck & Company, Inc. (Director · Dec 1, 2008 – May 25, 2018 · Past) | Director · Since at least Oct 3, 2022 |
| Charles A Baker Other companies: Progenics Pharmaceuticals Inc (Director · Jul 3, 2006 – Jun 13, 2012 · Past) | Director · Jan 3, 2006 – Jan 2, 2018 · Past |
| Marc Tessier-Lavigne Other companies: Denali Therapeutics Inc. (Director · Since at least May 30, 2019) | Director · Jan 2, 2020 – Jan 3, 2023 · Past |
All 56 people
| Person | Seat |
|---|---|
| Michael S. Brown Other companies: Pfizer, Inc. (Director · Apr 27, 2006 – Apr 28, 2011 · Past) | Distinguished Chair in Biomedical Sciences, Regental Professor of Molecular Genetics and Internal Medicine, and Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southweste · Since at least Jan 3, 2006 |
| Alexandra Bowie | Regeneron Investor Relations · Since at least Oct 1, 2026 |
| Andrew Murphy | Executive Vice President, Research and Co-Chief Scientific Officer · Since at least Dec 11, 2019 |
| Arthur F Ryan | Director · Since at least Apr 1, 2026 |
| Benjamin Yocum | Senior Vice President, Manufacturing Operations · Since at least Nov 4, 2026 |
| Brook Jennings | Senior Vice President, Global Immunology Commercial Business Unit · Since at least Nov 4, 2026 |
| Chris Fenimore | Executive Vice President, Finance and Chief Financial Officer · Since at least Nov 4, 2026 |
| Christina Chan | Corporate Communications · Since at least Sep 24, 2026 |
| Christopher R Fenimore | EVP Finance CFO · Since at least Mar 2, 2017 |
| Daniel Van Plew | Executive Vice President and General Manager, Industrial Operations and Product Supply · Since at least Apr 22, 2025 |
| Danilo Verge | Senior Vice President, Global Medical Affairs · Since at least Nov 4, 2026 |
| David Snow | Director · Since at least Feb 23, 2026 |
| Diana Hughes | Senior Vice President, Global Patient Safety · Since at least Nov 4, 2026 |
| Divya Pathak | Senior Vice President, Chief Artificial Intelligence Officer · Since at least Nov 4, 2026 |
| Eric M Shooter | Director · Jan 2, 2009 – Feb 12, 2014 · Past |
| George D. Yancopoulos | Board co-Chair, President and Chief Scientific Officer · Since at least Oct 30, 2015 |
| George Fraley | Senior Vice President, Associate General Counsel · Since at least Nov 4, 2026 |
| George L Sing | Director · Since at least Jan 2, 2024 |
| Huda Y Zoghbi | Director · Since at least Jan 2, 2020 |
| Ilana Yellen | Regeneron Investor Relations · Since at least Feb 27, 2026 |
| Jason Pitofsky | SVP Controller · Since at least Nov 7, 2025 |
| John Calabro | Senior Vice President, Internal Audit · Since at least Nov 4, 2026 |
| Joseph J. LaRosa | Executive Vice President, General Counsel and Secretary · Since at least Dec 16, 2011 |
| Joseph L. Goldstein | Professor of Molecular Genetics and Internal Medicine and Chair, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas · Since at least Mar 30, 2022 |
| Justin Holko | Senior Vice President, Global Oncology/Hematology Commercial Business Unit · Since at least Nov 4, 2026 |
| Kailey Kilmartin | Regeneron Investor Relations · Since at least Mar 24, 2026 |
| Kathryn Guarini | Director · Since at least Sep 8, 2023 |
| Kerry Reinertsen | Senior Vice President, Strategic Alliances · Since at least Nov 4, 2026 |
| Kevin Clark | Senior Vice President, Global Ophthalmology Commercial Business Unit · Since at least Nov 4, 2026 |
| L. Andres Sirulnik | Senior Vice President, Clinical Development Unit Head, Hematology · Since at least Nov 13, 2025 |
| Larry Coury | Senior Vice President, Associate General Counsel · Since at least Nov 4, 2026 |
| Leonard S. Schleifer | Board co-Chair, President and Chief Executive Officer · Since at least Mar 6, 2006 |
| Mack MacKenzie | Senior Vice President, Commercial and G&A Digital & Technology · Since at least Nov 4, 2026 |
| Marion McCourt | Executive Vice President, Commercial · Since at least Apr 1, 2022 |
| Mark Hudson | Investor Relations · Since at least Oct 25, 2026 |
| Matthew Everett | Senior Vice President, Global Procurement · Since at least Nov 4, 2026 |
| Melissa Lozner | Senior Vice President, Chief Compliance Officer · Since at least Nov 4, 2026 |
| Ned Braunstein | Executive Vice President, Regulatory Affairs, Global Patient Safety & Development Quality · Since at least Nov 4, 2026 |
| Neil Stahl | EVP Research and Development · Dec 9, 2020 – Dec 16, 2024 · Past |
| P Roy Vagelos | Director · Mar 30, 2022 – Apr 3, 2023 · Past |
| Richard Gluckselig | Senior Vice President, Associate General Counsel & Assistant Secretary · Since at least Nov 4, 2026 |
| Rick Hall | Senior Vice President, Human Resources and Chief Human Resources Officer · Since at least Nov 4, 2026 |
| Ryan Crowe | Senior Vice President, Investor Relations & Strategic Analysis · Since at least Nov 2, 2026 |
| Ryan Steinberger | Executive Vice President, Chief Digital & Technology Officer · Since at least Nov 5, 2026 |
| Sharon Chen | Regeneron Investor Relations · Since at least Dec 23, 2025 |
| Zoran Berkovic | Senior Vice President, Financial Planning and Analysis · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Regeneron Pharmaceuticals, Inc.